Skip to main content

Chris Cline

Head of Investor Relations

Travere Therapeutics, Inc. (TVTX)

Equibles does not estimate personal net worth.

Get an email with a short summary when Travere Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get TVTX alerts

About Chris Cline

Chris Cline is recorded as Head of Investor Relations at Travere Therapeutics, Inc. (TVTX). Chris Cline has spoken on 15 earnings calls across 1 company, most recently for Travere Therapeutics, Inc. on October 30, 2025. Travere Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Travere Therapeutics, Inc. includes Bradley Campbell (CEO and Board Member), Bradley L. Campbell (CEO and Board Member), Christopher Cline (CFO) and 7 others.

Chris Cline on recent calls

“This quarter, we delivered another strong set of financial results with continued significant revenue growth and disciplined financial investments.”
CFO, Travere Therapeutics, Inc. Q3 FY2025 Earnings Call ·
“As you heard from the rest of the team, we are pleased to report another quarter of great execution. This was driven by continued momentum in the ongoing FILSPARI launch and leveraging our strong financial foundation to strategically invest in the key priorities that are delivering growth now and in the future.”
CFO, Travere Therapeutics, Inc. Q1 FY2025 Earnings Call ·
“In the fourth quarter and entering the new year, our operations have continued to strengthen. As you heard from Peter, we have seen a meaningful inflection in net product sales of FILSPARI following full approval, and the outlook for the launch remains strong.”
CFO, Travere Therapeutics, Inc. Q4 FY2024 Earnings Call ·
“During the third quarter, our execution led to a significant increase in net product sales and disciplined investments in the areas we believe will drive growth.”
CFO, Travere Therapeutics, Inc. Q3 FY2024 Earnings Call ·
“During the second quarter, we achieved strong operational performance characterized by a significant rise in net product sales and a reduction in operating cash usage.”
CFO, Travere Therapeutics, Inc. Q2 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Travere Therapeutics, Inc.

Recent activity

Show 3 earlier activities